Leading cardiovascular hospital to develop vascular robotics program, improve patient care using the CorPath® GRX System

 

Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS) today announced that WakeMed Health & Hospitals will partner with Corindus to develop a national center of excellence to advance patient care and clinical robotics research and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions ("PCI") using the CorPath GRX System. WakeMed Health & Hospitals is the leading provider of health and cardiovascular services in Wake County, North Carolina.

RANCHO CORDOVA, Calif., March 15, 2017  -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care autologous cell-based therapies, today announced encouraging data from a study evaluating the use of autologous platelet rich plasma (PRP) for the treatment of chronic non-healing ulcers.

 

Results from the 24 patient study entitled “Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series” were published in the peer-reviewed, Journal of Biomedical Science. The study was led by researchers from TotipotentRX, a subsidiary of Cesca Therapeutics, and Fortis Memorial Research Institute.

TORONTO, ONTARIO--(March 7, 2017) -Spectral Medical Inc. ("Spectral" or the "Company")(TSX:EDT), a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced that it has received approval of the third module of its rolling PMA submission from the United States Food and Drug Administration ("FDA) for Toraymyxin™. The third PMA module details the device description and principles of operation and all manufacturing processes, including risk management and quality system integration.

 

"We are very encouraged with the FDA's response and approval of the third module. This follows our announcement on February 23, 2017, that we plan to file our fourth and final module containing clinical data early in the second quarter of this year," stated Dr. Paul Walker, President and CEO of Spectral. "The acceptance of the third PMA module by the FDA is another step forward on our regulatory pathway."

TORONTO, ONTARIO--(March 2, 2017) -Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSX VENTURE:VPT) announces that it has received a license from Health Canada for the new VMS-PLUS™ machine and the 4-chamber (4C) heart analysis system. This is an expansion of the VMS heart analysis product to include right atrium (RA), left atrium (LA) and left ventricle (LV) chambers of the heart. The VMS was already licensed in Canada for use for the right ventricle (RV). This expansion allows for the determination of volume and function for all four chambers of the heart using conventional 2D ultrasound, which could only be provided by MRI until now.